Clinical Trials on Choroidal Neovascularization in United Kingdom

Total 247 results

Novartis

Completed

Ranibizumab for the Treatment of Choroidal Neovascularisation (CNV) Secondary to Pathological Myopia (PM): an Individualized Regimen (REPAIR)

Choroidal Neovascularisation

United Kingdom
Pfizer

Terminated

A Study Of Early Markers Of Choroidal Neovascularization

Age-related Macular Degeneration (AMD) | Choroidal Neovascularization (CNV) | Early Markers

Italy, Portugal, United Kingdom
Salutaris Medical Devices, Inc.

Active, not recruiting

Episcleral Brachytherapy for the Treatment of Wet AMD (NEAMES)

Macular Degeneration, Choroidal Neovascularization

United States
Allergan

Terminated

Safety and Efficacy of Dexamethasone as Adjunctive Therapy to Ranibizumab in Subjects With Choroidal Neovascularization and Age-Related Macular Degeneration

Age-Related Maculopathy | Subfoveal Choroidal Neovascularization

United States
Oklahoma State University Center for Health Sciences

Completed

Intraocular Pressure Immediately Following Intravitreous Injection of Ranibizumab

Choroidal Neovascularization

United States
Vision Research Foundation
Genentech, Inc.

Completed

Evaluation of the Effect of Vitreous Composition Determined by Ultrasound and Optical Coherence Tomography (OCT) on Ranibizumab Therapy (PVD)

Choroidal Neovascularization

United States
Johns Hopkins University
Genentech, Inc.

Completed

Ranibizumab in Hemorrhagic Choroidal Neovascularization Trial

Choroidal Neovascularization

United States
Pfizer

Terminated

An Open Label Trial to Investigate Macugen for the Preservation of Visual Function in Subjects With Neovascular AMD (PERSPECTIVES)

Macular Degeneration | Age Related Macular Degeneration (AMD) | Choroidal Neovascularization (CNV)

Canada, Belgium, United Kingdom, France, Poland, Spain, Turkey, Czech Republic, Italy, Greece, Germany, Austria, Portugal, Denmark, Finland
Hoffmann-La Roche

Completed

Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (STAIRWAY)

Macular Degeneration, Age-Related | Neovascularization, Choroidal

United States
Novartis

Terminated

Verteporfin Photodynamic Therapy Administered in Conjunction With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)

Macular Degeneration | Choroidal Neovascularization

United Kingdom, Spain, Netherlands, Hungary, Italy, Denmark, Belgium, Austria, France, Germany, Poland, Switzerland
Oraya Therapeutics, Inc.

Unknown

An Open-label Study to Evaluate the Clinical and Economic Benefits of I-Ray in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (ENDEAVOUR)

Eye Diseases | Age-Related Macular Degeneration | Macular Degeneration | Retinal Diseases | Wet Macular Degeneration

United Kingdom
University of Utah
National Eye Institute (NEI)

Recruiting

Impact of Non-Exudative Type 1 MNV on AMD Progression

Age-Related Macular Degeneration | Neovascularization, Choroidal

United States
Allergan

Completed

Safety and Efficacy of a New Treatment as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) Treatment in Patients With Age-Related Macular Degeneration (AMD)

Choroidal Neovascularization | Age-Related Maculopathy

France, Korea, Republic of, New Zealand, Italy, Israel, United States, Portugal, Australia, United Kingdom
Ophthotech Corporation

Completed

A Study to Establish the Safety and Tolerability of Zimura® (Anti-C5 Aptamer) in Combination With Anti-VEGF Therapy in Subjects With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)

Idiopathic Polypoidal Choroidal Vasculopathy

United States
Ophthotech Corporation

Withdrawn

ZIMURA in Combination With Eylea in Patients With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)

Idiopathic Polypoidal Choroidal Vasculopathy

United States
RXi Pharmaceuticals, Corp.

Unknown

Evaluating RXI-109 to Reduce the Progression of Subretinal Fibrosis in Subjects With NVAMD

Age-related Macular Degeneration | Subfoveal Choroidal Neovascularization | Subretinal Scarring | Subretinal Fibrosis

United States
Allergan

Terminated

A Study Using Intravitreal Injections of a Small Interfering RNA in Patients With Age-Related Macular Degeneration

Age-Related Macular Degeneration | Choroid Neovascularization

United States, Australia, Philippines
Light Sciences LLC

Terminated

Study of Talaporfin Sodium Photodynamic Therapy to Treat Advanced Age Related Macular Disease

Macular Degeneration | Choroidal Neovascularization

United States
Novartis

Completed

Safety and Tolerability of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration

Subfoveal Choroidal Neovascularization (CNV) | Secondary to Age-related Macular Degeneration (AMD)

Germany, Belgium, Spain, Netherlands, United Kingdom, Hungary, Turkey, Israel, Portugal, Australia
Brandon G. Busbee, MD
Genentech, Inc.

Completed

Evaluation of Dosing Interval of Higher Doses of Ranibizumab (BGB/IST)

Macular Degeneration | Choroidal Neovascularization

United States
National Eye Institute (NEI)

Completed

Fluocinolone Implant to Treat Macular Degeneration

Macular Degeneration | Choroidal Neovascularization

United States
Eyetech Pharmaceuticals

Completed

Phase II/III Study of Anti-VEGF in Neovascular AMD

Macular Degeneration | Choroidal Neovascularization

United States
Novartis Pharmaceuticals
QLT Inc.

Completed

A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib (VERITAS)

Macular Degeneration | Choroidal Neovascularization

United States
Retinal Consultants Medical Group

Completed

Combination Bevacizumab and Verteporfin (Two Different Sequences of Treatment)in Neovascular AMD

Macular Degeneration | Choroidal Neovascularization

United States
Genentech, Inc.

Completed

A Study of rhuFab V2 (Ranibizumab) in Subjects With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)

Macular Degeneration

United States
Steba Biotech S.A.

Terminated

Safety and Preliminary Efficacy Study of WST11 (Stakel®)-Mediated VTP Therapy in Subjects With CNV Associated With AMD

Macular Degeneration | Choroidal Neovascularization

United States, France
Vitreous -Retina- Macula Consultants of New York
Genentech, Inc.

Withdrawn

Imatinib Mesylate Combined With Intravitreal Ranibizumab in the Treatment of Choroidal Neovascularization Secondary to Age-Related Macular Degeneration

Choroidal Neovascularization

United States
TargeGen

Terminated

Open-Label, Pilot Study of TG100801 in Patients With Choroidal Neovascularization Due to AMD

Macular Degeneration | Choroidal Neovascularization

United States
Theragenics Corporation

Unknown

Safety Study for Treatment of Wet Macular Degeneration Using the TheraSight(TM) Ocular Brachytherapy System

Macular Degeneration | Choroidal Neovascularization

United States
Barnes Retina Institute
Pfizer

Terminated

Macugen for Histoplasmosis

Choroidal Neovascularization | Ocular Histoplasmosis

United States
National Eye Institute (NEI)

Completed

Phase I Study of Corticosteroid Treatment of Ill-Defined Choroidal Neovascularization in Age-Related Macular Degeneration

Macular Degeneration | Choroidal Neovascularization

United States
Allergan

Completed

Safety and Efficacy of a New Therapy as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) in Subjects With Wet Age-Related Macular Degeneration (AMD)

Choroidal Neovascularization | Age-Related Maculopathy

United States, Australia, Philippines
University of Illinois at Chicago
ICON Bioscience Inc

Completed

20089 TA+Lucentis Combo Intravitreal Injections for Treatment of Neovascular Age-related Macular Degeneration (AMD) (20089/Combo)

Age-Related Macular Degeneration | Choroidal Neovascularization

United States
Novartis

Completed

Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization

Macular Degeneration | Choroidal Neovascularization

United States, Canada
QLT Inc.

Completed

Reduced Fluence Visudyne-Anti-VEGF-Dexamethasone In Combination for AMD Lesions (RADICAL) (RADICAL)

Macular Degeneration | Choroidal Neovascularization

United States, Canada
Washington University School of Medicine
Genentech, Inc.

Completed

CAPTAIN:Choroidal Neovascularization Assessment by Pattern Electroretinography (CAPTAIN)

Age-related Macular Degeneration

United States
National Eye Institute (NEI)

Completed

Identification and Treatment of Feeder Vessels in Macular Degeneration

Macular Degeneration

United States
Santen Inc.
MacuSight, Inc.

Terminated

Phase 1/2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Age-Related Macular Degeneration

Age-related Macular Degeneration | Choroidal Neovascularization

United States
Retina Research Institute, LLC

Completed

Intravitreal Aflibercept Injection (IAI) for Presumed Ocular Histoplasmosis Syndrome

Choroidal Neovascularization | Presumed Ocular Histoplasmosis

United States
Iconic Therapeutics, Inc.

Terminated

Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD) (DECO)

Choroidal Neovascularization | Wet Macular Degeneration

United States
Novartis Pharmaceuticals

Completed

Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients With nAMD (TREND)

Age-related Macular Degeneration | Choroidal Neovascularization

Korea, Republic of, Croatia, Germany, India, Russian Federation, Turkey, United Kingdom, Egypt, Israel, Belgium, Denmark, Hungary, Slovenia, Spain, Switzerland, Italy, Portugal, Slovakia, Chile
Retina Associates of Kentucky
Genentech, Inc.

Unknown

Intravitreal Ranibizumab for the Treatment of Choroidal Neovascularization in Ocular Histoplasmosis Syndrome (IVL for OHS)

Ocular Histoplasmosis Syndrome

United States
The Retina Center of St. Louis County, PC

Completed

Triple Combination Therapy of Choroidal Neovascularization in AMD, a Cost Effect and Efficient Therapeutic Treatment

Exudative Macular Degeneration

United States
California Retina Consultants
Novartis

Completed

Bevacizumab in Combination With Visudyne Photodynamic Therapy (PDT)

Macular Edema | Age Related Macular Degeneration | Choroidal Neovascularization

United States
Pfizer

Terminated

A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration

Age-Related Macular Degeneration

United States, United Kingdom, Australia, Netherlands
Oklahoma State University Center for Health Sciences
Novartis

Completed

Reduced Fluence Photodynamic Therapy (PDT) With Visudyne in Combination With Lucentis for Age-Related Macular Degeneration

Choroidal Neovascularization | Age-Related Maculopathy

United States
Johns Hopkins University

Completed

Age-related Macular Degeneration: Detection of Onset of New Choroidal Neovascularization (AMD DOC Study)

Choroidal Neovascularization | Maculopathy, Age-Related

United States
Michael Abramoff
National Eye Institute (NEI)

Completed

Retinal Therapy Guided by 3D OCT Image Analysis

Age-Related Macular Degeneration | Choroidal Neovascularization

United States
Johns Hopkins University
Oregon Health and Science University

Completed

Neovascular Age Related Macular Degeneration (AMD), Periocular Corticosteroids, and Photodynamic Therapy (PDT)

Age-Related Macular Degeneration | Choroidal Neovascularization

United States
National Eye Institute (NEI)

Completed

Infliximab, Sirolimus and Daclizumab to Treat Age-Related Macular Degeneration (AMDB1)

Age-Related Macular Degeneration | Choroidal Neovascularization

United States

Clinical Trials on Choroidal Neovascularization in United Kingdom

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mali

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations